This is the authors' abstract. We don't add key points for this paper.
Tumour hypoxia stems from impaired oxygen delivery as a result of a disorganised tumour vasculature and inadequate blood supply. Hypoxic tumours are highly resistant to chemotherapy and radiation therapy and correlate with a poor patient prognosis. Hypoxia is a powerful stimulus for the expression of genes involved in cell survival and angiogenesis. A key factor in this process is hypoxia-inducible factor (HIF), which regulates transcription of hypoxia-activated genes. Efforts are currently under way to develop targeted cancer therapeutics to hypoxia-activated pathways, and in particular to the transcription factor HIF.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Carroll et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: